MNKD

Quote

Short

News

Articles

Message Board

MannKind Corporation (NASDAQ : MNKD ) News

MannKind Corporation (NASDAQ: MNKD) News Releases

MNKD News Releases

June 05, 2026 07:35:00 pm

GlobeNewswire

Data at ADA 2026 Highlights Key Findings from Clinical and Real?World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

June 03, 2026 06:05:00 am

GlobeNewswire

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

June 02, 2026 10:40:35 pm

SeekingAlpha

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

June 01, 2026 12:00:06 am

KlickAnalytics

MNKD Price Target Alert: $11.00. Issued by Wells Fargo

May 29, 2026 07:24:04 pm

SeekingAlpha

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

May 29, 2026 02:00:00 pm

GlobeNewswire

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

May 29, 2026 01:35:34 pm

SeekingAlpha

MannKind gains FDA nod to expand inhaled insulin for children

May 29, 2026 12:30:00 pm

GlobeNewswire

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

May 27, 2026 04:00:00 pm

GlobeNewswire

MannKind to Present at Jefferies Global Healthcare Conference

May 27, 2026 09:05:00 am

GlobeNewswire

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account